Status:
COMPLETED
Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents
Lead Sponsor:
GlaxoSmithKline
Conditions:
Meningococcal Disease
Eligibility:
All Genders
10-19 years
Phase:
PHASE2
Brief Summary
This is extension of the V102\_16 study (NCT02140762). V102\_16E1 is designed to assess the effectiveness of a 3-dose vaccination series of MenABCWY, administered according to 0, 2, 6 month schedule, ...
Eligibility Criteria
Inclusion
- Adolescents who completed V102\_16 study and received the study vaccines as assigned in the protocol (either two doses of the MenABCWY or one dose each of MenACWY and Placebo).
Exclusion
- Serious, acute, or chronic illnesses. Previous or suspected disease caused by N. meningitidis.
- History of any meningococcal vaccine administration other than vaccination given in the parent V102\_16 protocol.
Key Trial Info
Start Date :
December 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 11 2015
Estimated Enrollment :
189 Patients enrolled
Trial Details
Trial ID
NCT02285777
Start Date
December 1 2014
End Date
June 11 2015
Last Update
September 24 2018
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Huntsville, Alabama, United States, 35802
2
GSK Investigational Site
Jonesboro, Arkansas, United States, 72401
3
GSK Investigational Site
Melbourne, Florida, United States, 32934
4
GSK Investigational Site
Newton, Kansas, United States, 67114